Clinical Trial Update: Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib (Nexavar) versus placebo as maintenance therapy in advanced ovarian or primary peritoneal cancer; results were posted in 2012…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2012-11-30